. Author manuscript; available in PMC: 2014 Jun 1.

Published in final edited form as: Gynecol Oncol. 2013 Mar 13;129(3):538–543. doi: 10.1016/j.ygyno.2013.03.004

Table 4. Multivariate Analysis of Factors Associated with Survival.

Variable		Multivariate Analysis Hazard Ratio (95% CI)
Management of perforation	Conservative (n=15))	Referent
Management of perforation	Surgical (n=28)	0.88 (0.32-2.57)
Extent of cancer present at time of perforation	No evidence of disease (n=8)	Referent
	Microscopic disease/Localized disease (n=10)	6.13 (0.78-60.11)
	Peritoneal carcinomatosis/Distant metastasis (n=22)	^*42.20 (3.28-639.83)
Cancer-directed surgery	No (n=11)	Referent
Cancer-directed surgery	Yes (n=31)	0.54 (0.08-4.74)
Number of Chemotherapy regimens	<2 (n=17)	Referent
	≥2 (n=14)	0.92 (0.27-3.25)
	None/Unknown (n=12)	0.29 (0.07-1.22)
Stage	I/II (n=16)	Referent
	III/IV (n=21)	0.98 (0.22-5.53)
	Unknown (n=6)	2.23 (0.34-18.29)
CA-125	<100 (n=10)	Referent
	≥100 (n=16)	1.90 (0.51-7.29)
	Unknown (n=17)	1.21 (0.21-6.52)

p<0.05